IRadimed Corp (IRMD) stock
IRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3060% above fair value
$85.35+0.12 (+0.14%)
Close on Nov 13, 2026Market cap $1.09BP/E 45.6Yield –
IRadimed EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
IRadimed's EPS for the twelve months ending Sep 30, 2026 was $1.87, up 13.3% year over year. For fiscal 2025 it was $1.75, up 16.7% from the year before. Over ten years it grew 11.3% a year on average. The highest annual figure on record is $1.75 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.75 | +16.7% |
| FY2024 | Dec 31, 2024 | $1.50 | +11.1% |
| FY2023 | Dec 31, 2023 | $1.35 | +32.4% |
| FY2022 | Dec 31, 2022 | $1.02 | +37.8% |
| FY2021 | Dec 31, 2021 | $0.74 | +572.7% |
| FY2020 | Dec 31, 2020 | $0.11 | -85.9% |
| FY2019 | Dec 31, 2019 | $0.78 | +50.0% |
| FY2018 | Dec 31, 2018 | $0.52 | +1200.0% |
| FY2017 | Dec 31, 2017 | $0.04 | -93.3% |
| FY2016 | Dec 31, 2016 | $0.60 | 0.0% |
| FY2015 | Dec 31, 2015 | $0.60 | +200.0% |
| FY2014 | Dec 31, 2014 | $0.20 | -9.1% |
| FY2013 | Dec 31, 2013 | $0.22 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.51 | +18.6% |
| Q2 FY2026 | Jun 30, 2026 | $0.41 | -8.9% |
| Q1 FY2026 | Mar 31, 2026 | $0.45 | +21.6% |
| Q4 FY2025 | Dec 31, 2025 | $0.50 | +25.0% |
| Q3 FY2025 | Sep 30, 2025 | $0.43 | +7.5% |
| Q2 FY2025 | Jun 30, 2025 | $0.45 | +18.4% |
| Q1 FY2025 | Mar 31, 2025 | $0.37 | +15.6% |
| Q4 FY2024 | Dec 31, 2024 | $0.40 | +11.1% |
| Q3 FY2024 | Sep 30, 2024 | $0.40 | 0.0% |
| Q2 FY2024 | Jun 30, 2024 | $0.38 | +15.2% |
| Q1 FY2024 | Mar 31, 2024 | $0.32 | +18.5% |
| Q4 FY2023 | Dec 31, 2023 | $0.36 | +24.1% |
| Q3 FY2023 | Sep 30, 2023 | $0.40 | +48.1% |
| Q2 FY2023 | Jun 30, 2023 | $0.33 | +26.9% |
| Q1 FY2023 | Mar 31, 2023 | $0.27 | +35.0% |
| Q4 FY2022 | Dec 31, 2022 | $0.29 | -6.5% |
| Q3 FY2022 | Sep 30, 2022 | $0.27 | +35.0% |
| Q2 FY2022 | Jun 30, 2022 | $0.26 | +116.7% |
| Q1 FY2022 | Mar 31, 2022 | $0.20 | +81.8% |
| Q4 FY2021 | Dec 31, 2021 | $0.31 | +520.0% |
| Q3 FY2021 | Sep 30, 2021 | $0.20 | +122.2% |
| Q2 FY2021 | Jun 30, 2021 | $0.12 | – |
| Q1 FY2021 | Mar 31, 2021 | $0.11 | -21.4% |
| Q4 FY2020 | Dec 31, 2020 | $0.05 | -80.8% |
| Q3 FY2020 | Sep 30, 2020 | $0.09 | -55.0% |
| Q2 FY2020 | Jun 30, 2020 | -$0.17 | -200.0% |
| Q1 FY2020 | Mar 31, 2020 | $0.14 | -6.7% |
| Q4 FY2019 | Dec 31, 2019 | $0.26 | +85.7% |
| Q3 FY2019 | Sep 30, 2019 | $0.20 | 0.0% |
| Q2 FY2019 | Jun 30, 2019 | $0.17 | +54.5% |
| Q1 FY2019 | Mar 31, 2019 | $0.15 | +114.3% |
| Q4 FY2018 | Dec 31, 2018 | $0.14 | +600.0% |
| Q3 FY2018 | Sep 30, 2018 | $0.20 | +900.0% |
| Q2 FY2018 | Jun 30, 2018 | $0.11 | +266.7% |
| Q1 FY2018 | Mar 31, 2018 | $0.07 | – |
| Q4 FY2017 | Dec 31, 2017 | $0.02 | -80.0% |
| Q3 FY2017 | Sep 30, 2017 | $0.02 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.03 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.02 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.10 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?